WALTHAM, Mass., Jan. 9, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG), a specialty pharmaceutical company, announced today that William Heiden, AMAG's chief executive officer, will provide an update on the company followed by a breakout session at the 32nd Annual J.P. Morgan Healthcare Conference on January 15, 2014 at 8:00 a.m. Pacific Time. During the presentation and breakout session, the company's business, regulatory status, strategy and growth prospects will be discussed.
A live audio webcast of the company's presentation and the following breakout session along with the accompanying slide presentation will be accessible through the Investors section of the company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 15, 2014.
AMAG Pharmaceuticals, Inc. is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. AMAG currently markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. The company's primary goal is to bring to market therapies that provide clear benefits and improve patients' lives. For additional company information, please visit www.amagpharma.com.
CONTACT: AMAG Pharmaceuticals, Inc. Contact:
Amy Sullivan, 617-498-3303
Source: AMAG Pharmaceuticals, Inc.